Decapeptide GnRH analog — D-Trp⁶ substitution stabilises against pituitary peptidases. Like leuprolide, an initial LH/FSH/testosterone flare (clinically relevant in prostate cancer — pre-treat with anti-androgen) transitions to chronic pituitary GnRH-R desensitisation and castrate gonadal steroids within ~3–4 weeks. Depot microsphere / embonate salt formulations provide 1, 3, or 6 month durations of action.
Half-Life & Elimination Curve (IM: 4h)
Plasma (IM)t½ Decay (4h)
0×t½0h100%(19.3 µg/L)
1×t½4h50%(9.64 µg/L)
2×t½8h25%(4.82 µg/L)
3×t½12h12.5%(2.41 µg/L)
4×t½16h6.3%(1.2 µg/L)
5×t½20h3.1%(0.602 µg/L)
Elimination t½4h (IM)
Rate Constant (ke)0.173 h⁻¹
Time to Peak (Tmax)12.2h
Est. Peak (Cmax)19.3 µg/L
Clearance (CL)3.64 L/h
97% Washout (5×t½)20h
Dosing Guidelines
Intramuscular (IM): Typical 3.75 mg
Subcutaneous (SC): Typical 3.75 mg
Pharmacokinetic Parameters
Intramuscular (IM): Bioavailability (F): 90% · Volume of Distribution (Vd): 21 L · Absorption (ka): 0.03 h⁻¹ (t½ka ≈ 23.1h) [PMID 20166771]